Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Leukemia
•
ALL
•
AYA
•
Hematology
•
Pediatric Oncology
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
Related Questions
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
